Beam Therapeutics Inc. Common Stock
Veridion Score
Composite trend over time
Why is BEAM moving today?
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BEAM.
BEAM insider activity
Beam Therapeutics Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for BEAM.
BEAM contract awards, year to date.
Public federal awards linked to this ticker.
BEAM lobbying filings, year to date.
Registered lobbying filings matched to Beam Therapeutics Inc. Common Stock.